Today: 9 April 2026
Subscribe
Browse Category

SGX:AIY 10 December 2025 - 8 February 2026

iFAST Stock (SGX:AIY) News, Forecasts and Outlook on 13 Dec 2025: What’s Driving iFAST Corporation Shares?

iFAST Stock (SGX:AIY) News, Forecasts and Outlook on 13 Dec 2025: What’s Driving iFAST Corporation Shares?

iFAST shares closed at S$9.55 on 12 December 2025, near the 52-week high of S$9.99, with a market cap of S$2.9 billion. The company reported record 3Q2025 net profit of S$26.01 million, up 54.7% year-on-year, and assets under administration at S$30.62 billion, up 29.6%. Hong Kong ePension drove profit before tax in Hong Kong to S$19.39 million, a 46.4% increase.
13 December 2025
·
iFAST Corporation Ltd Stock (SGX: AIY): Share Price Near 52-Week High as Analysts Lift Targets; Key Catalysts and Outlook on 12 Dec 2025

iFAST Corporation Ltd Stock (SGX: AIY): Share Price Near 52-Week High as Analysts Lift Targets; Key Catalysts and Outlook on 12 Dec 2025

iFAST shares traded at S$9.55 on 12 Dec 2025, near their 52-week high, after Q3 net profit surged 54.7% year-on-year to S$26.01 million and assets under administration hit a record S$30.62 billion. Market cap stood at S$2.89 billion. Fresh policy debate in Singapore on post-trade custody has put iFAST’s platform model in focus.
12 December 2025
·

Stock Market Today

  • AbbVie's Humira Launch on TrumpRx with 86% Discount Sparks Valuation Questions
    April 9, 2026, 9:02 AM EDT. AbbVie (NYSE:ABBV) has introduced Humira on the TrumpRx platform at an 86% discount under a White House pricing deal aiming to reduce patient costs and widen drug access. This marks a significant US pricing strategy shift post exclusivity for Humira, a key immunology therapy driving substantial revenue. The stock trades near $206.69, about 20% below analyst targets and 43.8% under fair value estimates. The deep discount could alter patient volume, payer ties, and pricing benchmarks in government-linked drug programs. AbbVie's revenue exposure of $61.2 billion and a high price-to-earnings ratio of 87.3 place focus on potential impacts to cash flow and dividends amid its debt load. Investors should monitor reactions from payers, competitors, and capital markets to this pricing shift that could redefine AbbVie's US market dynamics.

Latest article

When Will Gas Prices Fall? Iran Ceasefire May Not Bring Quick Relief as Oil Rebounds

When Will Gas Prices Fall? Iran Ceasefire May Not Bring Quick Relief as Oil Rebounds

9 April 2026
Brent crude rebounded 3% Thursday despite a U.S.-Iran ceasefire, with the Strait of Hormuz still nearly shut and only one oil-products tanker passing in 24 hours. U.S. gasoline averaged $4.166 a gallon on April 9, and AAA said prices could drop slowly. North Sea Forties crude hit a record $146.43 a barrel. The U.S. EIA expects Hormuz flows may take months to recover.
CoreWeave Stock Climbs on $21 Billion Meta AI Cloud Deal, but Debt Risks Stay in Focus

CoreWeave Stock Climbs on $21 Billion Meta AI Cloud Deal, but Debt Risks Stay in Focus

9 April 2026
CoreWeave said Meta Platforms committed about $21 billion for AI cloud capacity through December 2032. Shares rose 4.3% to $88.90 in premarket trading after the announcement. The deal follows an $8.5 billion loan facility and a $1.25 billion senior notes offering. CoreWeave reported $5.13 billion in 2025 revenue and ended December with a $66.8 billion backlog.
NVIDIA’s Rubin AI Chip Ramp Hits Fresh Snag as HBM4 Memory Crunch Clouds 2026

NVIDIA’s Rubin AI Chip Ramp Hits Fresh Snag as HBM4 Memory Crunch Clouds 2026

9 April 2026
TrendForce said April 8 that Nvidia’s Rubin AI chip shipments may be delayed by HBM4 memory qualification and cooling demands, shifting over 70% of 2026 high-end GPU volume to the current Blackwell line. Rubin’s projected share dropped to 22%. Samsung began shipping HBM4 to Nvidia in February, but SK Hynix and Micron face qualification delays. Broadcom signed a long-term deal to develop Google’s TPUs through 2031.
Go toTop